BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 33569661)

  • 1. Molecular-Driven Therapy in Advanced Thyroid Cancer.
    Miller KC; Chintakuntlawar AV
    Curr Treat Options Oncol; 2021 Feb; 22(3):24. PubMed ID: 33569661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging Therapies for Radioactive Iodine Refractory Thyroid Cancer.
    Kirtane K; Roth MY
    Curr Treat Options Oncol; 2020 Feb; 21(3):18. PubMed ID: 32048061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel targeted therapies and immunotherapy for advanced thyroid cancers.
    Naoum GE; Morkos M; Kim B; Arafat W
    Mol Cancer; 2018 Feb; 17(1):51. PubMed ID: 29455653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer.
    Narayanan S; Colevas AD
    Curr Treat Options Oncol; 2016 Jun; 17(6):30. PubMed ID: 27139457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current Advances in Thyroid Cancer Management. Are We Ready for the Epidemic Rise of Diagnoses?
    Rusinek D; Chmielik E; Krajewska J; Jarzab M; Oczko-Wojciechowska M; Czarniecka A; Jarzab B
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28829399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nodal metastases in thyroid cancer: prognostic implications and management.
    Wang LY; Ganly I
    Future Oncol; 2016 Apr; 12(7):981-94. PubMed ID: 26948758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thyroid Gland Malignancies.
    Cabanillas ME; Dadu R; Hu MI; Lu C; Gunn GB; Grubbs EG; Lai SY; Williams MD
    Hematol Oncol Clin North Am; 2015 Dec; 29(6):1123-43. PubMed ID: 26568552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Development of PD-1/PD-L1 Inhibitors in Breast Cancer: Still a Long Way to Go.
    Barroso-Sousa R; Tolaney SM
    Curr Treat Options Oncol; 2020 Jun; 21(7):59. PubMed ID: 32556894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal Management of Patients with Advanced NSCLC Harboring High PD-L1 Expression and Driver Mutations.
    Chen JA; Riess JW
    Curr Treat Options Oncol; 2020 Jun; 21(7):60. PubMed ID: 32588244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Therapies in Advanced Gastric Cancer.
    Patel TH; Cecchini M
    Curr Treat Options Oncol; 2020 Jul; 21(9):70. PubMed ID: 32725377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Advanced radioiodine-refractory differentiated thyroid cancer].
    Spitzweg C; Auernhammer CJ; Geisler J; Böck S; Heinemann V; Bartenstein P; Göke B
    Dtsch Med Wochenschr; 2015 Feb; 140(3):168-71. PubMed ID: 25658401
    [No Abstract]   [Full Text] [Related]  

  • 12. New Therapies for Advanced Thyroid Cancer.
    Laha D; Nilubol N; Boufraqech M
    Front Endocrinol (Lausanne); 2020; 11():82. PubMed ID: 32528402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical therapy for advanced forms of thyroid cancer.
    Rajhbeharrysingh U; Taylor M; Milas M
    Surg Clin North Am; 2014 Jun; 94(3):541-71. PubMed ID: 24857576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting vascular endothelial growth factor (VEGF) pathway in iodine-refractory differentiated thyroid carcinoma (DTC): from bench to bedside.
    Abdel-Rahman O
    Crit Rev Oncol Hematol; 2015 Apr; 94(1):45-54. PubMed ID: 25560732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake.
    Lee YA; Lee H; Im SW; Song YS; Oh DY; Kang HJ; Won JK; Jung KC; Kwon D; Chung EJ; Hah JH; Paeng JC; Kim JH; Choi J; Kim OH; Oh JM; Ahn BC; Wirth LJ; Shin CH; Kim JI; Park YJ
    J Clin Invest; 2021 Sep; 131(18):. PubMed ID: 34237031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of immune checkpoint inhibitors in anaplastic thyroid cancer (Case Series).
    Sukari A; Kukreja G; Nagasaka M; Shukairy MK; Yoo G; Lin HS; Hotaling J; Kim H
    Oral Oncol; 2020 Oct; 109():104744. PubMed ID: 32402656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress in molecular-based management of differentiated thyroid cancer.
    Xing M; Haugen BR; Schlumberger M
    Lancet; 2013 Mar; 381(9871):1058-69. PubMed ID: 23668556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Aggressive Thyroid Cancer.
    Huang J; Harris EJ; Lorch JH
    Surg Pathol Clin; 2019 Dec; 12(4):943-950. PubMed ID: 31672300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multikinase Inhibitor Treatment in Thyroid Cancer.
    Ancker OV; Krüger M; Wehland M; Infanger M; Grimm D
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31861373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenvatinib: Role in thyroid cancer and other solid tumors.
    Cabanillas ME; Habra MA
    Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.